AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37581275 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Brain Reorienting (DBR)
Number of subjects: 54
Study 37581275 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (WL) control
Number of subjects: 54
Study 37581385 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Trimethylamine
Number of subjects: 0
Study 37581388 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study 37581388 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel
Number of subjects: 0
Study 37581390 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular (RV) systolic dysfunction
Number of subjects: 90
Study 37581394 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI) in patients with ATTR-CM
Number of subjects: 0
Study 37581394 — intervention group
Group type: COMPARATOR
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 0
Study 37581498 — intervention group
Group type: COMPARATOR
Intervention: Contrast-enhanced mammography (CEM)
Number of subjects: 246
Study 37581498 — intervention group
Group type: COMPARATOR
Intervention: Abbreviated breast MRI (ABMRI)
Number of subjects: 246
Study 37581498 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard breast MRI
Number of subjects: 246
Study 37581593 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab with CHOP chemotherapy
Number of subjects: 40
Study 37581616 — intervention group
Group type: EXPERIMENTAL
Intervention: Binimetinib
Number of subjects: 341
Study 37581616 — intervention group
Group type: COMPARATOR
Intervention: Physician's choice of chemotherapy (PCC)
Number of subjects: 341
Study 37581619 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallium-68-labelled DOTATATE
Number of subjects: 22
Study 37581673 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal estrogen (1 g of conjugated estrogen cream, 0.625 mg/g)
Number of subjects: 206
Study 37581673 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 206
Study 37581673 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal estrogen
Number of subjects: 206
Study 37581909 — intervention group
Group type: EXPERIMENTAL
Intervention: Domestic Violence Intervention (DeVI) combining Problem Management Plus counseling and violence prevention component
Number of subjects: 912
Study 37581909 — intervention group
Group type: COMPARATOR
Intervention: Control arm (standard care)
Number of subjects: 912
Study 37581981 — intervention group
Group type: EXPERIMENTAL
Intervention: Midostaurin (50 mg twice daily) plus chemotherapy (idarubicin or daunorubicin) for 21 days
Number of subjects: 301
Study 37581981 — intervention group
Group type: COMPARATOR
Intervention: Midostaurin (50 mg twice daily) plus chemotherapy
Number of subjects: 301
Study 37582084 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary function tests (PFT)
Number of subjects: 100
Study 37582084 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest computed tomography (CT)
Number of subjects: 100
Study 37582084 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal CT findings (bronchiectasis, reticulation, ground-glass opacities)
Number of subjects: 100
Study 37582097 — intervention group
Group type: EXPERIMENTAL
Intervention: PNE program + MR program
Number of subjects: 72
Study 37582097 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional biomedical information + MR program
Number of subjects: 72
Study 37582097 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study 37582096 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of fructose-containing sugars (excess energy from sugars added)
Number of subjects: 5213
Study 37582096 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit and 100% fruit juice (low doses, up to or less than ~10% E)
Number of subjects: 5213
Study 37582096 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed sources (with sugar-sweetened beverages [SSBs]) at high doses (up to 23%)
Number of subjects: 5213
Study 37582096 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of SSBs (up to ~20% E)
Number of subjects: 5213
Study 37582096 — intervention group
Group type: COMPARATOR
Intervention: Substitution, subtraction, or ad libitum trials of total fructose-containing sugars
Number of subjects: 5213
Study 37582154 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic bronchoscopic and transthoracic navigation
Number of subjects: 0
Study 37582169 — intervention group
Group type: EXPERIMENTAL
Intervention: State-of-the-art PCI
Number of subjects: 754
Study 37582169 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 754
Study 37582170 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricuspid transcatheter edge-to-edge repair with the TriClip implant
Number of subjects: 85
Study 37582265 — intervention group
Group type: EXPERIMENTAL
Intervention: Teledermatology
Number of subjects: 664
Study 37582274 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37582340 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary revascularization (SR)
Number of subjects: 869
Study 37582340 — intervention group
Group type: COMPARATOR
Intervention: No myocardial revascularization failure (MRF)
Number of subjects: 869
Study 37582340 — intervention group
Group type: COMPARATOR
Intervention: Disease progression
Number of subjects: 869
Study 37582474 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual physical therapy (3 sessions)
Number of subjects: 120
Study 37582474 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 120
Study 37582633 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational drug use (positive test for recreational drugs)
Number of subjects: 1499
Study 37582633 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis, cocaine, and MDMA use (assessed separately)
Number of subjects: 1499
Study 37582633 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple drug detection (28% of positive patients)
Number of subjects: 1499
Study 37582633 — intervention group
Group type: COMPARATOR
Intervention: No recreational drug use (negative test)
Number of subjects: 1499
Study 37582719 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous passive paracentesis for up to 7 days
Number of subjects: 70
Study 37582719 — intervention group
Group type: COMPARATOR
Intervention: Large-volume paracentesis (LVP) performed intermittently according to clinical practice, maximum duration of 8 hours
Number of subjects: 70
Study 37582730 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary catheterization (CC) procedure once
Number of subjects: 136495
Study 37582730 — intervention group
Group type: COMPARATOR
Intervention: Coronary catheterization (CC) procedure twice
Number of subjects: 136495
Study 37582730 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary catheterization (CC) procedure
Number of subjects: 136495
Study 37582736 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive goal setting
Number of subjects: 512
Study 37582736 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate reinforcement
Number of subjects: 512
Study 37582736 — intervention group
Group type: COMPARATOR
Intervention: Delayed reinforcement
Number of subjects: 512
Study 37582736 — intervention group
Group type: COMPARATOR
Intervention: Static goal setting
Number of subjects: 512
Study 37582746 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led social mobilisation into community-based integrated adolescent and youth friendly HIV and sexual and reproductive health care
Number of subjects: 40
Study 37582746 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (UTT and PrEP) delivered through primary health clinics
Number of subjects: 40
Study 37582775 — intervention group
Group type: EXPERIMENTAL
Intervention: Gingivitis
Number of subjects: 314
Study 37582775 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontitis Stage III
Number of subjects: 314
Study 37582775 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontitis Stage II
Number of subjects: 314
Study 37582775 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontitis Stage I
Number of subjects: 314
Study 37582775 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI increase
Number of subjects: 314
Study 37582945 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab and oligo-fractionated irradiation (22.5 Gy/5 fractions/5 days)
Number of subjects: 40
Study 37582952 — intervention group
Group type: EXPERIMENTAL
Intervention: Elranatamab (subcutaneous, once weekly after two step-up priming doses)
Number of subjects: 123
Study 37582952 — intervention group
Group type: EXPERIMENTAL
Intervention: Elranatamab (biweekly dosing after six cycles for persistent responders)
Number of subjects: 123
Study 37582952 — intervention group
Group type: EXPERIMENTAL
Intervention: Elranatamab (overall treatment)
Number of subjects: 123
Study 37582952 — intervention group
Group type: EXPERIMENTAL
Intervention: Elranatamab (biweekly dosing)
Number of subjects: 123
Study 37583261 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate dehydrogenase levels
Number of subjects: 235
Study 37583261 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood viscosity
Number of subjects: 235
Study 37583267 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/glycopyrrolate/formoterol fumarate (BGF)
Number of subjects: 0
Study 37583267 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI)
Number of subjects: 0
Study 37583434 — intervention group
Group type: EXPERIMENTAL
Intervention: High preoperative blood levels of oxaloacetate
Number of subjects: 67
Study 37583434 — intervention group
Group type: EXPERIMENTAL
Intervention: High preoperative blood levels of 2-aminoadipic acid (2-AAA)
Number of subjects: 67
Study 37583434 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without dNCR)
Number of subjects: 67
Study 37583699 — intervention group
Group type: COMPARATOR
Intervention: Multiple sclerosis patients
Number of subjects: 0
Study 37583699 — intervention group
Group type: COMPARATOR
Intervention: Relapsing multiple sclerosis
Number of subjects: 0
Study 37583699 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue-Factor
Number of subjects: 0
Study 37583699 — intervention group
Group type: EXPERIMENTAL
Intervention: Top-5 discriminating variables for model (1)
Number of subjects: 0
Study 37583699 — intervention group
Group type: EXPERIMENTAL
Intervention: Top-5 discriminating variables for model (2)
Number of subjects: 0
Study 37583881 — intervention group
Group type: EXPERIMENTAL
Intervention: EMA-based phone counseling and instant messaging for smoking cessation
Number of subjects: 0
Study 37583881 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 0
Study 37583905 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 37583905 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo or standard care)
Number of subjects: 0
Study 37583920 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% hypertonic saline (HS)
Number of subjects: 40
Study 37583920 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 40
Study 37584207 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-therapy sirolimus-eluting and CD34 antibody-coated COMBO stent (DTS)
Number of subjects: 3146
Study 37584207 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting Orsiro stent (SES)
Number of subjects: 3146
Study 37584233 — intervention group
Group type: EXPERIMENTAL
Intervention: Amulet occluder
Number of subjects: 1878
Study 37584233 — intervention group
Group type: COMPARATOR
Intervention: Watchman device
Number of subjects: 1878
Study 37584254 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV 10 mg/AML 5 mg
Number of subjects: 259
Study 37584254 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV 20 mg/AML 5 mg
Number of subjects: 259
Study 37584254 — intervention group
Group type: COMPARATOR
Intervention: ATV 20 mg/AML 5 mg
Number of subjects: 259
Study 37584273 — intervention group
Group type: EXPERIMENTAL
Intervention: N. gonorrheae/C. trachomatis positive cases
Number of subjects: 605
Study 37584273 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic treatment
Number of subjects: 605
Study 37584290 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab plus carfilzomib and dexamethasone (Isa-Kd)
Number of subjects: 61
Study 37584290 — intervention group
Group type: COMPARATOR
Intervention: Carfilzomib and dexamethasone (Kd)
Number of subjects: 61
Study 37584291 — intervention group
Group type: EXPERIMENTAL
Intervention: Close surveillance instead of upfront hematopoietic stem cell transplantation (HSCT)
Number of subjects: 7
Study 37584291 — intervention group
Group type: EXPERIMENTAL
Intervention: Close surveillance instead of upfront HSCT
Number of subjects: 7
Study 37584291 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic HSCT
Number of subjects: 7
Study 37584292 — intervention group
Group type: EXPERIMENTAL
Intervention: Red cell distribution width (RDW) measurement
Number of subjects: 0
Study 37584292 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment for refractory chronic GVHD
Number of subjects: 0
Study 37584309 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant porcine factor VIII (rpFVIII)
Number of subjects: 53
Study 37584344 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted vaccine
Number of subjects: 619
Study 37584344 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vaccine
Number of subjects: 619
Study 37584344 — intervention group
Group type: COMPARATOR
Intervention: Standard vaccine
Number of subjects: 619
Study 37584362 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients developing MINS
Number of subjects: 72
Study 37584362 — intervention group
Group type: COMPARATOR
Intervention: Patients without MINS
Number of subjects: 72
Study 37584365 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitra sampling for pharmacokinetic evaluations
Number of subjects: 0
Study 37584370 — intervention group
Group type: EXPERIMENTAL
Intervention: LB-100
Number of subjects: 0
Study 37584370 — intervention group
Group type: EXPERIMENTAL
Intervention: endothall
Number of subjects: 0
Study 37584370 — intervention group
Group type: COMPARATOR
Intervention: LB-105 and endothall-D6
Number of subjects: 0
Study 37584609 — intervention group
Group type: EXPERIMENTAL
Intervention: Active individuals
Number of subjects: 0
Study 37584609 — intervention group
Group type: COMPARATOR
Intervention: Insulin resistance individuals
Number of subjects: 0
Study 37584841 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) extended-release buprenorphine (BPN) depots (CAM2038)
Number of subjects: 252
Study 37584841 — intervention group
Group type: COMPARATOR
Intervention: Sublingual (SL) buprenorphine (BPN)
Number of subjects: 252
Study 37584841 — intervention group
Group type: EXPERIMENTAL
Intervention: SC CAM2038 weekly and monthly
Number of subjects: 252
Study 37584898 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin pamoate 15 mg administered on day 1 and at months 3, 6, and 9
Number of subjects: 32
Study 37585220 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal swabs
Number of subjects: 0
Study 37585220 — intervention group
Group type: COMPARATOR
Intervention: Lower respiratory tract samples
Number of subjects: 0
Study 37585243 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered web-based dietary recall
Number of subjects: 194
Study 37585243 — intervention group
Group type: COMPARATOR
Intervention: Interviewer-administered 24-hour dietary recall
Number of subjects: 194
Study 37585253 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Number of subjects: 0
Study 37585253 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37585254 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine
Number of subjects: 0
Study 37585254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37585260 — intervention group
Group type: EXPERIMENTAL
Intervention: mobile app + volunteer support + TAU (volunteers)
Number of subjects: 40
Study 37585260 — intervention group
Group type: EXPERIMENTAL
Intervention: mobile app + TAU (apps)
Number of subjects: 40
Study 37585260 — intervention group
Group type: COMPARATOR
Intervention: TAU only (TAU)
Number of subjects: 40
Study 37585282 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivot (mobile smoking cessation program)
Number of subjects: 188
Study 37585282 — intervention group
Group type: COMPARATOR
Intervention: QuitGuide (control)
Number of subjects: 188
Study 37585454 — intervention group
Group type: EXPERIMENTAL
Intervention: DME patients (1,502)
Number of subjects: 11005
Study 37585454 — intervention group
Group type: COMPARATOR
Intervention: Non-DME controls (5,603)
Number of subjects: 11005
Study 37585569 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-phased telehealth model for PTSD treatment
Number of subjects: 0
Study 37585628 — intervention group
Group type: EXPERIMENTAL
Intervention: GNT0003 (gene therapy) - higher dose
Number of subjects: 5
Study 37585628 — intervention group
Group type: EXPERIMENTAL
Intervention: GNT0003 (gene therapy) - lower dose
Number of subjects: 5
Study 37585628 — intervention group
Group type: EXPERIMENTAL
Intervention: GNT0003 (gene therapy)
Number of subjects: 5
Study 37585627 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy alone (no radiotherapy)
Number of subjects: 500
Study 37585652 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery during Lockdown 2
Number of subjects: 253
Study 37585652 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery during Lockdown 3
Number of subjects: 253
Study 37585652 — intervention group
Group type: EXPERIMENTAL
Intervention: Women patients
Number of subjects: 253
Study 37585652 — intervention group
Group type: COMPARATOR
Intervention: All cohorts
Number of subjects: 253
Study 37585730 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-angiography (CTA) screening for intracranial aneurysms (IAs)
Number of subjects: 500
Study 37586052 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibegron treatment, dosage and duration not specified
Number of subjects: 0
Study 37586057 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibegron
Number of subjects: 0
Study 37586057 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 37586317 — intervention group
Group type: EXPERIMENTAL
Intervention: TAEST16001 T cell therapy after dose-reduced lymphodepletion with cyclophosphamide (15 mg/kg/day × 3 days) and fludarabine (20 mg/m2/day)
Number of subjects: 0
Study 37586350 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (n = 40)
Number of subjects: 66
Study 37586350 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment (n = 26)
Number of subjects: 66
Study 37586364 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide adenine dinucleotide (NAD) treatment; specific dosage and duration not mentioned
Number of subjects: 0
Study 37586364 — intervention group
Group type: COMPARATOR
Intervention: Control group; specific details not mentioned
Number of subjects: 0
Study 37586475 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab (100 mg subcutaneously every 4 weeks for 52 weeks)
Number of subjects: 0
Study 37586475 — intervention group
Group type: COMPARATOR
Intervention: Placebo (every 4 weeks for 52 weeks)
Number of subjects: 0
Study 37586560 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-weekly home food delivery from the local food bank
Number of subjects: 160
Study 37586560 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-weekly financial assistance with healthy food access navigation
Number of subjects: 160
Study 37586560 — intervention group
Group type: COMPARATOR
Intervention: Traditional CHW services, nutrition educational materials, and provision of basic essential cooking tools
Number of subjects: 160
Study 37586649 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergonomic infant carrier and instructions on proper use
Number of subjects: 100
Study 37586649 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (control group)
Number of subjects: 100
Study 37586823 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 211
Study 37586823 — intervention group
Group type: COMPARATOR
Intervention: Dual antiplatelet therapy
Number of subjects: 211
Study 37586835 — intervention group
Group type: EXPERIMENTAL
Intervention: Descemet's membrane endothelial keratoplasty (DMEK)
Number of subjects: 8998
Study 37586835 — intervention group
Group type: COMPARATOR
Intervention: Penetrating keratoplasty (PKP)
Number of subjects: 8998
Study 37586835 — intervention group
Group type: COMPARATOR
Intervention: Descemet's stripping (automated) endothelial keratoplasties (DSAEKs)
Number of subjects: 8998
Study 37586835 — intervention group
Group type: COMPARATOR
Intervention: Deep anterior lamellar keratoplasties (DALKs)
Number of subjects: 8998
Study 37586845 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine treatment 0.5 mg two times per day
Number of subjects: 40
Study 37586845 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study 37586845 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine treatment
Number of subjects: 40
Study 37586862 — intervention group
Group type: EXPERIMENTAL
Intervention: biomodulation protocol (cryobiomodulation, photobiomodulation, electrobiomodulation) administered during the first 6 weeks after surgery
Number of subjects: 146
Study 37586862 — intervention group
Group type: COMPARATOR
Intervention: control group (no additional biomodulation protocol)
Number of subjects: 146
Study 37586869 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy (pre-CRT)
Number of subjects: 0
Study 37586869 — intervention group
Group type: COMPARATOR
Intervention: Up-front surgery
Number of subjects: 0
Study 37586882 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-ProS derived from 14 differentially expressed proteins (DEPs) identified through LASSO analysis.
Number of subjects: 420
Study 37586882 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-ProS validated in an independent internal validation cohort of 71 patients with nongenetic PD and 35 HCs.
Number of subjects: 420
Study 37586882 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-ProS using 5 of the 14 DEPs measured in the LCC.
Number of subjects: 420
Study 37586882 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-ProS for distinguishing genetic PD from genetic prodromals.
Number of subjects: 420
Study 37586882 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-ProS predicting cognitive decline in PD.
Number of subjects: 420